VNRX | VolitionRx Limited Stock Overview

(Stock Exchange: AMEX)

Day's Range	0.5810 - 0.6772
52 Week Range	0.4300 - 1.2300
Beta	1.23
Implied Volatility	432.23%
IV Rank	100.00%
Day's Volume	401,292
Average Volume	271,674
Shares Outstanding	95,967,800
Market Cap	64,864,636
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2012-03-02

Valuation
Profitability
Growth
Health
P/E Ratio	-1.88
Forward P/E Ratio	N/A
EPS	-0.36
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	101
Country	USA
Website	VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

VNRX's peers: ECOR, CFMS, EVGN, EOLS, OCX, STRR

*Chart delayed

Analyzing fundamentals for VNRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see VNRX Fundamentals page.

Watching at VNRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on VNRX Technicals page.